BSX
BOSTON SCIENTIFIC CORP
NYSE · Healthcare · Medical - Devices · US
$45.82
+5.33%Year over year
Reported trailing growth
- Revenue
- +8.9%
- EBITDA
- +7.8%
- EBIT
- +32.2%
- EPS
- +25.4%
- Free cash flow
- -11.8%
- Operating cash flow
- -8.5%
Forward estimates
Based on analyst estimates
- Revenue
- -1.8%
- EBITDA
- +34.4%
- EPS
- +30.4%
Three-year CAGR
- Revenue
- +16.5%
- EBITDA
- +23.0%
- EBIT
- +29.6%
- Net income
- +60.5%
- EPS
- +63.5%
- Free cash flow
- +58.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026